2023
Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)
Kewan T, Bewersdorf J, Blaha O, Stahl M, Al Ali N, DeZern A, Sekeres M, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, Amaya M, Zeidner J, Savona M, Stempel J, Chandhok N, Logothetis C, Ramaswamy R, Rose A, Roboz G, Rolles B, Wang E, Harris A, Shallis R, Xie Z, Padron E, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan A. Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA). Blood 2023, 142: 3240. DOI: 10.1182/blood-2023-186340.Peer-Reviewed Original ResearchComplete remission rateOverall response rateOutcome of ptsMedian overall survivalOverall survivalHypomethylating agentHMA initiationHR-MDSC-indexRisk groupsScoring systemInternational Prognostic Scoring SystemResponse criteriaPrognostic scoring systemHigh-risk diseaseLarge multicenter cohortHigh-risk groupHarrell's C-indexLog-rank testPrediction of outcomeDifferent scoring systemsSubsequent validation studiesHMA cyclesMedian followAllogeneic HSCTValidation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)
Kewan T, Bewersdorf J, Blaha O, Stahl M, Al Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, Amaya M, Zeidner J, Savona M, Stempel J, Chandhok N, Logothetis C, Cochran H, Rose A, Roboz G, Wang E, Rolles B, Harris A, Shallis R, Xie Z, Padron E, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan A. Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT). Blood 2023, 142: 4980. DOI: 10.1182/blood-2023-186578.Peer-Reviewed Original ResearchOverall survivalHigh-risk groupUnderwent HSCTC-indexRisk groupsHigh riskDonor typeInternational Prognostic Scoring SystemAllogenic stem cell transplantationTime of HSCTMedian overall survivalReduced-intensity conditioningSignificant OS differencePrognostic scoring systemRisk stratification toolTime of diagnosisStem cell transplantationSingle-institution analysisLog-rank testHarrell's C-indexDifferent overall survivalCox proportional hazardsHMA cyclesHaploidentical donorsMaintenance therapy
2015
Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better?
Zeidan AM, Sekeres MA, Wang X, Al Ali N, Garcia‐Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS, Consortium O. Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better? American Journal Of Hematology 2015, 90: 1036-1040. PMID: 26284571, DOI: 10.1002/ajh.24173.Peer-Reviewed Original ResearchConceptsInternational Prognostic Scoring SystemIPSS-R categoryLR-MDSHarrell's C-indexOverall survivalC-indexLower-risk myelodysplastic syndromesRevised International Prognostic Scoring SystemActual overall survivalMedian overall survivalVaried survival outcomesKaplan-Meier methodPrognostic scoring systemDisease-modifying therapiesCategory 3Eligible patientsPoor OSPrognostic utilitySurvival outcomesMyelodysplastic syndromePrognostic valueLarge cohortPatientsEarly interventionScoring systemComparing the Prognostic Value of Risk stratifying Models for Patients with Lower‐Risk Myelodysplastic Syndromes: Is one model better?
Zeidan A, Sekeres M, Wang X, Al Ali N, Garcia‐Manero G, Steensma D, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski J, List A, Komrokji R. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower‐Risk Myelodysplastic Syndromes: Is one model better? American Journal Of Hematology 2015 PMCID: PMC4751065, DOI: 10.1002/ajh.24170.Peer-Reviewed Original ResearchInternational Prognostic Scoring SystemIPSS-R categoryLR-MDSHarrell's C-indexOverall survivalC-indexLower-risk myelodysplastic syndromesRevised International Prognostic Scoring SystemActual overall survivalMedian overall survivalVaried survival outcomesKaplan-Meier methodPrognostic scoring systemDisease-modifying therapiesCategory 3Eligible patientsPoor OSPrognostic utilitySurvival outcomesMyelodysplastic syndromePrognostic valueLarge cohortPatientsEarly interventionScoring system